SEC Form 4 · accession 0000899243-18-004667
Wave Life Sciences, Inc. · WVE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael A. Panzara
Officer — Franchise Lead, Neurology
Period of report
Feb 15, 2018
Accepted (ET)
Feb 20, 2018 · 7:34 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631574
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Feb 15, 2018 | M | 18,750 | $21.69 | A | 58,486 | D | |
| Ordinary Shares | Feb 15, 2018 | S | 18,750 | $50.00 | D | 39,736 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (right to buy)F2 | $21.69 | Feb 15, 2018 | M | 18,750 | D | — | Jul 11, 2026 | Ordinary Shares | 18,750 | 131,250 | D |
Explanation of responses
- F1The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017.
- F2The share option represented a right to purchase a total of 150,000 ordinary shares, 25% of which became exercisable on July 11, 2017, and the remaining shares vest in 36 equal monthly installments thereafter.